In vitro and in vivo evaluation of cyclodextrin-based nanosponges for enhancing oral bioavailability of atorvastatin calcium

References

• Sharma K, Kumar K, Mishra N. Nanoparticulate carrier system: a novel treatment approach for hyperlipidemia. Drug Deliv. 2016;23:684–699.
   Web of Science ®Google Scholar
• WHO [Internet]. Raised cholesterol. 2008 [cited 2016 Dec 7]. Available from: http://www.who.int/gho/ncd/risk_factors/cholesterol_text/en/
   Google Scholar
• Anwar M, Warsi MH, Mallick N, et al. Enhanced bioavailability of nano-sized chitosan–atorvastatin conjugate after oral administration to rats. Eur J Pharm Sci. 2011;44:241–249.
   PubMed Web of Science ®Google Scholar
• Kim J-S, Kim M-S, Park HJ, et al. Physicochemical properties and oral bioavailability of amorphous atorvastatin hemi-calcium using spray-drying and SAS process. Int J Pharm. 2008;359:211–219.
   PubMed Web of Science ®Google Scholar
• Shen H, Zhong M. Preparation and evaluation of self-microemulsifying drug delivery systems (SMEDDS) containing atorvastatin. J Pharm Pharmacol. 2006;58:1183–1191.
   PubMed Web of Science ®Google Scholar
• Zhang H-X, Wang J-X, Zhang Z-B, et al. Micronization of atorvastatin calcium by antisolvent precipitation process. Int J Pharm. 2009;374:106–113.
   PubMed Web of Science ®Google Scholar
• Sharma K, Hallan SS, Lal B, et al. Development and characterization of floating spheroids of atorvastatin calcium loaded NLC for enhancement of oral bioavailability. Artif Cells Nanomed Biotechnol. 2016;44:1448–1456.
   PubMed Web of Science ®Google Scholar
• Ibrahim AH, Ibrahim HM, Ismael HR, et al. Optimization and evaluation of lyophilized fenofibrate nanoparticles with enhanced oral bioavailability and efficacy. Pharm Dev Technol. 2017;38:78–89.
   Google Scholar
• Lemsi M, Galai H, Louhaichi MR, et al. Amorphization of atorvastatin calcium by mechanical process: characterization and stabilization within polymeric matrix. J Pharm Innovation. 2017;12:216–225.
   Web of Science ®Google Scholar
• Elbahwy IA, Ibrahim HM, Ismael HR, et al. Enhancing bioavailability and controlling the release of glibenclamide from optimized solid lipid nanoparticles. J Drug Deliv Sci Technol. 2017;38:78–89.
   Web of Science ®Google Scholar
• Cavalli R, Trotta F, Tumiatti W. Cyclodextrin-based nanosponges for drug delivery. J Incl Phenom Macrocycl Chem. 2006;56:209–213.
   Web of Science ®Google Scholar
• Torne S, Darandale S, Vavia P, et al. Cyclodextrin-based nanosponges: effective nanocarrier for Tamoxifen delivery. Pharm Dev Technol. 2013;18:619–625.
   PubMed Web of Science ®Google Scholar
• Davankov V, Ilyin M, Tsyurupa M, et al. From a dissolved polystyrene coil to an intramolecularly-hyper-cross-linked “Nanosponge”. Macromolecules. 1996;29:8398–8403.
   Web of Science ®Google Scholar
• Guo L, Gao G, Liu X, et al. Preparation and characterization of TiO 2 nanosponge. Mater Chem Phys. 2008;111:322–325.
   Web of Science ®Google Scholar
• Farrell D, Limaye SY, Subramanian S. Silicon nanosponge particles. Google Patents WO2006121870A3. 2009.
   Google Scholar
• Swaminathan S, Pastero L, Serpe L, et al. Cyclodextrin-based nanosponges encapsulating camptothecin: physicochemical characterization, stability and cytotoxicity. Eur J Pharm Biopharm. 2010;74:193–201.
   PubMed Web of Science ®Google Scholar
• Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J Pharm Sci. 1996;85:1017–1025.
   PubMed Web of Science ®Google Scholar
• Trotta F, Tumiatti W, Cavalli R, et al. Cyclodextrin-based nanosponges as a vehicle for antitumoral drugs. Google Patents WO2009003656A1. 2009.
   Google Scholar
• Ansari KA, Vavia PR, Trotta F, et al. Cyclodextrin-based nanosponges for delivery of resveratrol: in vitro characterisation, stability, cytotoxicity and permeation study. AAPS PharmSciTech. 2011;12:279–286.
   PubMed Web of Science ®Google Scholar
• Trotta F, Cavalli R, Tumiatti W, et al. Ultrasound-assisted synthesis of cyclodextrin-based nanosponges. Google Patents WO2006002814A1. 2005.
   Google Scholar
• Trotta F, Tumiatti W. Cross-linked polymers based on cyclodextrins for removing polluting agents. Google Patents US20050154198A1. 2003.
   Google Scholar
• Szejtli J, Szente L. Elimination of bitter, disgusting tastes of drugs and foods by cyclodextrins. Eur J Pharm Biopharm. 2005;61:115–125.
   PubMed Web of Science ®Google Scholar
• Choudhary A, Rana AC, Aggarwal G, et al. Development and characterization of an atorvastatin solid dispersion formulation using skimmed milk for improved oral bioavailability. Acta Pharmaceutica Sinica B. 2012;2:421–428.
   Google Scholar
• Balakumar K, Raghavan CV, Abdu S. Self nanoemulsifying drug delivery system (SNEDDS) of rosuvastatin calcium: design, formulation, bioavailability and pharmacokinetic evaluation. Colloids Surf B Biointerfaces. 2013;112:337–343.
   PubMed Web of Science ®Google Scholar
• Vilà L, Rebollo A, Ađalsteisson GS, et al. Reduction of liver fructokinase expression and improved hepatic inflammation and metabolism in liquid fructose-fed rats after atorvastatin treatment. Toxicol Appl Pharmacol. 2011;251:32–40.
   PubMed Web of Science ®Google Scholar
• Hussein AK, Ibrahim MA, Amin MA, et al. Improved in vitro dissolution parameters and in vivo hypolipidemic efficiency of atorvastatin calcium through the formation of hydrophilic inclusion complex with cyclodextrins. Drug Dev Res. 2011;72:379–390.
   Web of Science ®Google Scholar
• Rossi B, Fontana A, Giarola M, et al. Glass-like dynamics of new cross-linked polymeric systems: behavior of the Boson peak. J Non-Cryst Solids. 2014;401:73–77.
   Web of Science ®Google Scholar
• Zhang L, Han L, Sun X, et al. The use of PEGylated liposomes to prolong the circulation lifetime of salvianolic acid B. Fitoterapia. 2012;83:678–689.
   PubMed Web of Science ®Google Scholar
• Ali KA, Mukherjee B, Bandyopadhyay AK. Formulation development and in vitro evaluation of solidified self-microemulsion in the form of tablet containing atorvastatin calcium. Drug Dev Ind Pharm. 2013;39:1742–1749.
   PubMed Web of Science ®Google Scholar
• Kassem AM, Ibrahim HM, Samy AM. Development and optimisation of atorvastatin calcium loaded self-nanoemulsifying drug delivery system (SNEDDS) for enhancing oral bioavailability: in vitro and in vivo evaluation. J Microencapsul. 2017;23:1–15.
   Google Scholar
• Mady FM, Abou‐Taleb AE, Khaled KA, et al. Enhancement of the aqueous solubility and masking the bitter taste of famotidine using drug/SBE-beta-CyD/povidone K30 complexation approach. J Pharm Sci. 2010;99:4285–4294.
   PubMed Web of Science ®Google Scholar
• Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221–1231.
   PubMed Web of Science ®Google Scholar